Review clinical classifications, diagnostic procedures, and management strategies for cardiomyopathy and heart failure in this comprehensive overview.

Polygenic background bidirectionally modifies the penetrance of pathogenic variants in hypertrophic (HCM) and dilated (DCM) ...

Idiopathic dilated cardiomyopathy (IDC) is defined by the presence of left ventricular dilatation and systolic dysfunction in the absence of an underlying cause, such as hypertension, valve disease or ...

Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, ...

Dilated Cardiomyopathy is a heart muscle disease that starts in the left ventricle and affects the pumping chamber. The ventricle in such case is not able to pump blood properly through it because the ...

Social determinants of health (SDOH) were found to be associated with increased risk of heart failure (HF) and ventricular arrhythmias (VA) in patients with hypertrophic cardiomyopathy (HCM), ...

The results of research by scientists at University College London (UCL), Imperial College London, and the MRC Laboratory of Medical Sciences, indicate that a potentially life-changing heart condition ...

Dilated cardiomyopathy is an uncommon complication of hypothyroidism. Clinicians should consider dilated cardiomyopathy in patients with generalized pitting edema. Cardiac dysfunction in patients with ...

While management of dilated cardiomyopathy (DCM) patients whose ejection fraction recovers to above 40% has been becoming more clear, some aspects of optimal medication strategy remain muddy. Release ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...